Overview

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel